Open | - |
Close | - |
Volume / Avg. | 28.406K / 13.028M |
Day Range | - - - |
52 Wk Range | 0.081 - 5.980 |
Market Cap | $3.510M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 42 |
Short Interest | 1.05% |
Days to Cover | 1 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Kintara Therapeutics (NASDAQ: KTRA) through any online brokerage.
Other companies in Kintara Therapeutics’s space includes: Tharimmune (NASDAQ:THAR), Synaptogenix (NASDAQ:SNPX), Cyclacel Pharmaceuticals (NASDAQ:CYCC), Geovax Labs (NASDAQ:GOVX) and Finch Therapeutics Gr (NASDAQ:FNCH).
The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Maxim Group on Friday, July 14, 2023. The analyst firm set a price target for 14.00 expecting KTRA to rise to within 12 months (a possible 15472.86% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Kintara Therapeutics (NASDAQ: KTRA) is $0.0899 last updated Today at March 19, 2024 at 5:15 AM EDT.
There are no upcoming dividends for Kintara Therapeutics.
Kintara Therapeutics’s Q3 earnings are confirmed for Thursday, May 9, 2024.
There is no upcoming split for Kintara Therapeutics.
Kintara Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.